Ivosidenib in the treatment of metastatic cholangiocarcinoma – a case report

Česká verze

Authors: J. Kopecký ¹; P. Hoffmann ²; P. Priester ¹; M. Kristlová ¹
Authors place of work: Klinika onkologie a radioterapie LF v Hradci Králové UK a FN Hradec Králové ¹; Radiologická klinika LF v Hradci Králové UK a FN Hradec Králové ²
Published in the journal: Klin Onkol 2025; 38(2): 148-152
Category: Kazuistiky
doi: https://doi.org/10.48095/ccko2025148

Summary

Background: Cholangiocarcinoma is an aggressive cancer with an increasing incidence and a poor prognosis, typically resulting in a median survival of about 12 months for advanced cases. The standard treatment has been platinum-based systemic chemotherapy, although its effectiveness is often limited. Genetic alterations, such as mutations in the IDH1 gene, offer potential targets for targeted therapies, particularly in patients with intrahepatic cholangiocarcinoma. Ivosidenib, an oral IDH1 inhibitor, has shown improved progression-free survival in patients with IDH1-mutated cholangiocarcinoma, according to phase III ClarIDHy study. Observation: We present the case of a 62-year-old patient diagnosed with advanced cholangiocarcinoma and an IDH1 mutation. The patient initially responded to standard chemotherapy, which led to a temporary stabilisation of the disease; however, progression was noted after 6 months. Given the presence of the IDH1 alteration, the patient was treated with ivosidenib as a second-line therapy. This treatment resulted in disease stabilisation according to RECIST criteria. Subjectively, the patient experienced a significant improvement in the quality of life. The patient achieved more than three times longer progression-free survival than was achieved in the clinical trial, without the need for dose reduction. Conclusion: This case highlights the importance of targeted therapy for patients with IDH1-mutated cholangiocarcinoma. Not only was objective disease stabilisation achieved, but there was also a significant subjective improvement in the quality of life. This underscores the value of molecular testing and supports the use of personalised medicine when treating rare cancer types like cholangiocarcinoma, even in instances where objective responses are relatively uncommon.

Keywords:

cholangiocarcinoma – palliative care – targeted therapy – ivosidenib – molecular predictors

Zdroje

1. Krenzien F, Nevermann N, Krombholz A et al. Treatment of intrahepatic cholangiocarcinoma –⁠ a multidisciplinary approach. Cancers 2022; 14 (2): 362. doi: 10.3390/cancers14020362.

2. Saha SK, Zhu AX, Fuchs CS et al. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist 2016; 21 (5): 594–599. doi: 10.1634/theoncologist.2015-0446.

3. Elgenidy A, Afifi AM, Jalal PK. Survival and causes of death among patients with intrahepatic cholangiocarcinoma in the United States from 2000 to 2018. Cancer Epidemiol Biomarkers Prev 2022; 31 (12): 2169–2176. doi: 10.1158/1055-9965.EPI-22-0444.

4. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part III: liver, biliary tract, and pancreas. Gastroenterology 2009; 136 (4): 1134–1144. doi: 10.1053/j.gastro.2009.02.038.

5. Valle J, Wasan H, Palmer DH et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362 (14): 1273–1281. doi: 10.1056/NEJMoa0908721.

6. Lamarca A, Palmer DH, Wasan HS et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol 2021; 22 (5): 690–701. doi: 10.1016/S1470-2045 (21) 00027-9.

7. Oh DY, He AR, Qin S et al. 56P updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC). Ann Oncol 2022; 33: S565–S566. doi: 10.1016/j.annonc.2022.07.084.

8. Kelley RK, Ueno M, Yoo C et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 401 (10391): 1853–1865. doi: 10.1016/S0140-6736 (23) 00727-4.

9. Drilon A, Laetsch TW, Kummar S et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018; 378 (8): 731–739. doi: 10.1056/NEJMoa1714448.

10. Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372 (26): 2509–2520. doi: 10.1056/NEJMoa1500596.

11. Zhu AX, Macarulla T, Javle MM et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol 2021; 7 (11): 1669–1677. doi: 10.1001/jamaoncol.2021.3836.

12. Boscoe AN, Rolland C, Kelley RK. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol 2019; 10 (4): 751–765. doi: 10.21037/jgo.2019.03.10.

13. Mondesir J, Willekens C, Touat M et al. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. J Blood Med 2016; 7 : 171–180. doi: 10.2147/JBM.S70716.

14. Popovici-Muller J, Lemieux RM, Artin E et al. Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett 2018; 9 (4): 300–305. doi: 10.1021/acsmedchemlett.7b00421.